Cargando…
A trial of nonspecific immunotherapy using systemic C. parvum in treated patients with Dukes B and C colorectal cancer.
In view of the relatively poor prognosis for patients after surgery for locally invasive colorectal cancer a trial of repeated systemic infusions of Corynebacterium parvum (CP) has been carried out. It is in this group of patients, with a high risk of recurrence from small residues of cancer left by...
Autores principales: | Souter, R. G., Gill, P. G., Morris, P. J. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1982
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2010994/ https://www.ncbi.nlm.nih.gov/pubmed/7041943 |
Ejemplares similares
-
The utility of Aspirin in dukes C and high risk dukes B colorectal cancer - The ASCOLT study: study protocol for a randomized controlled trial
por: Ali, Raghib, et al.
Publicado: (2011) -
Molecular Characterization of Somatic Alterations in Dukes’ B and C Colorectal Cancers by Targeted Sequencing
por: Abdul, Shafina-Nadiawati, et al.
Publicado: (2017) -
Contribution of plasminogen activators and their inhibitors to the survival prognosis of patients with Dukes' stage B and C colorectal cancer.
por: Ganesh, S., et al.
Publicado: (1997) -
Complement activation in vivo in cancer patients receiving C. parvum immunotherapy.
por: Biran, H., et al.
Publicado: (1976) -
Failure of specific active immunotherapy in lung cancer.
por: Souter, R. G., et al.
Publicado: (1981)